Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Telik Raises USD5 Million in Venture Financing 13
Telik Raises USD4.6 Million in Venture Financing 14
Mabvax Therapeutics Raises US$12 Million In Venture Financing 15
MabVax Therapeutics Raises US$5.2 Million In First Tranche Of Series B Financing 16
Partnerships 17
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20
Licensing Agreements 21
Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21
Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22
MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23
Equity Offering 24
MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24
MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25
MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27
MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28
MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29
MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30
MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31
MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32
MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33
MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35
MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38
MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42
MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43
MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44
Debt Offering 45
MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45
Acquisition 46
Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46
MabVax Therapeutics Holdings Inc – Key Competitors 48
MabVax Therapeutics Holdings Inc – Key Employees 49
MabVax Therapeutics Holdings Inc – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
Jul 24, 2017: MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives 51
Financial Announcements 52
Apr 02, 2018: MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones 52
May 24, 2017: MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results 54
Corporate Communications 55
Aug 01, 2018: MabVax Therapeutics announces board of director changes 55
Jul 05, 2018: MabVax Therapeutics Receives Nasdaq Delist Determination 56
Jun 27, 2018: MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q 57
Apr 13, 2018: MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq’s Minimum Stockholders’ Equity Requirements 58
Feb 15, 2018: MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement 59
Legal and Regulatory 60
Sep 21, 2018: Delaware Court of Chancery grants petition fied by MabVax Therapeutics 60
Sep 11, 2018: MabVax Therapeutics files suit against Sichenzia Ross Ference, a law firm that formerly represented the company in certain corporate, securities, and securities and exchange commission matters 61
Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 62
Aug 03, 2018: Delaware Court of Chancery sets hearing date On petition filed By MabVax Therapeutics 63
Jul 27, 2018: MabVax Therapeutics Files Delaware Petition 64
Product News 65
09/13/2017: MabVax Therapeutics HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress 65
Product Approvals 66
Jan 09, 2017: MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075 66
Clinical Trials 67
Jun 05, 2017: MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting 67
May 25, 2017: MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting 68
Feb 23, 2017: MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer 69
Feb 13, 2017: MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 70
Other Significant Developments 71
Jan 16, 2018: MabVax Therapeutics Holdings Provides Business Strategy Update 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Telik Raises USD5 Million in Venture Financing 13
Telik Raises USD4.6 Million in Venture Financing 14
Mabvax Therapeutics Raises US$12 Million In Venture Financing 15
MabVax Therapeutics Raises US$5.2 Million In First Tranche Of Series B Financing 16
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20
Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21
Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22
MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23
MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24
MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25
MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27
MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28
MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29
MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30
MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31
MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32
MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33
MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35
MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38
MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42
MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43
MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44
MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45
Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46
MabVax Therapeutics Holdings Inc, Key Competitors 48
MabVax Therapeutics Holdings Inc, Key Employees 49
MabVax Therapeutics Holdings Inc, Subsidiaries 50
List of Figures
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10